Emergent BioSolutions has announced positive two-year mid-stage trial results for its chikungunya virus vaccine hopeful.

According to the company, phase 2 trial participants given a single dose of the chikungunya virus vaccine candidate, CHIKV VLP, showed serum-neutralizing antibodies at a rate 19 times higher than pre-vaccination titers after two years.

Additionally, inoculation with the vaccine candidate was well-tolerated and did not lead to any significant safety concerns, with the majority of adverse events being mild or moderate in severity, Emergent said. The trial enrolled 415 healthy adults.

As a result of the phase 2 findings on the CHIKV VLP vaccine, the company intends to launch a phase 3 trial this year, using a single adjuvanted 40 µg dose, according to Karen Smith, Emergent’s executive vice president and chief medical officer.